ASX Announcement (ASX: AXE) 13 July 2023

Archer transfers biochipgraphene sensor technology design to a commercial fab to verify scalability

Highlights

HIGHLIGHTS

• Archer Materials has successfully completed a proof ofconcept biosensing graphene transistor for use in its biochip.

• The design has been submitted to a commercial foundryfor a Multi-Project Wafer run.

• Fabrication at commercial foundries to verify the scalabilityof Archer’s design will occur in coming months with delivery of chips expectedby the end of 2023.

• Archer has started discussions with potential globalfoundry partners for initial small production runs of its graphene chip designsto evaluate the reliability of the product.

• This is a major step towards the potential commercialisationof Archer’s biochip technology.

SHAPE \* MERGEFORMAT

Archer Materials Limited (“Archer”, the “Company”, “ASX: AXE”), a semiconductorcompany advancing the quantum computing and medical diagnostics industries, hascompleted a proof of concept biosensing graphene transistor for use in itsbiochip, and submitted the technology design to a commercial foundry to verifyscalability.

Technology design transfer of gFET to a commercial semiconductor foundry

Archer is transferring its first generation graphene fieldeffect transistor (“gFET”) design to a foundry partner, following thecompletion of its optical lithography-compatible chip layout for its gFETdevice.

Archer’s optical lithography has electrodes, bond pads, andother graphene componentry, that allow the biochip’s sensor device design toscale more easily to produce complete wafers in collaboration with commercialfoundries.

The Archer-designed gFET sensing chips will be produced by acommercial foundry, with the aim of Archer validating its design to ensureappropriate scalability for the manufacturing process. Archer expects completedruns to arrive at the end of 2023. The runs will be evaluated to test whichfoundry and process are best suited to Archer’s technology. Archer’s design andprocess can then be scaled to manufacture complete wafers containing thegraphene-based sensors for biochip integration in collaboration with a range ofdifferent commercial foundries.

Archer has, in parallel,started discussions with potential global foundry partners for initial smallproduction runs of its graphene chip designs to evaluate the reliability of theproduct. The latest development follows the recent announcement on 10 March2023 in which the Company gained electronic control of the sensitivity of itsincorporated gFET devices so it can better target biomolecules. This followedArcher’s early-stage biochip prototype with an integrated system platform forbiosensing announced to the market on 16 November 2022, after having developeda ‘wettable’ gFET announced on 24 October 2022.

1

Archer Materials ArcherMaterials Limited (ACN: 123 993 233)

Technology LotFourteen, Frome Road, Adelaide SA 5000

www.archerx.com.au

Commenting on the biochip technology transfer to a commercial fab, DrMohammad Choucair, CEO of Archer, said,

“Archer has made some impressive progress of its biochip byessentially transferring the core sensing technology from concept to design. Wehave done this in-house and now look to have it externally fabricated, so itcan be foundry compatible and scaled to manufacture. The team is also currentlyimproving its functionality to better detect diseases.

“Developing the biochip is an important project for not onlyArcher, but for the broader world we live in. There is a heightened focusaround the globe to detect and prevent disease. Archer’s biochip aims to doboth through a highly sensitive graphene material and powerful data analyticsthat seeks to improve on-chip disease diagnosis and health outcomes. This willtruly make it a ‘Lab-on-a-Chip’.”

The Board ofArcher authorised this announcement to be given to ASX.

Investor enquiries Media enquiries

Eric Kuret Tristan Everett +61 417 311 335 +61 403 789096

[email protected] [email protected]